Abstract
Effective non-genetic disease modifying treatments for Huntington’s disease (HD) will necessarily target multiple diverse neurodegenerative processes triggered by mutant huntingtin. Neurotrophin receptors are well-positioned for this task as they regulate signaling pathways that largely overlap with signaling networks contributing to HD-related synaptic dysfunction, glial activation, excitotoxicity, and other degenerative processes. This review will discuss the contributions of disrupted neurotrophin receptor-related signaling to primary HD neuropathologies, and prospects for harnessing this signaling to develop therapeutics to counteract HD degenerative mechanisms. Application of the native protein ligands has been challenging pharmacologically, but progress has been made with the advent of small molecule compounds that can selectively bind to and activate specific Trk receptors or p75NTR to promote trophic and/or inhibit degenerative signaling in cell populations preferentially affected in HD.
CNS & Neurological Disorders - Drug Targets
Title:Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
Volume: 16 Issue: 3
Author(s): Danielle A. Simmons, Frank M. Longo and Stephen M. Massa*
Affiliation:
- Department of Neurology, San Francisco VAMC and UCSF, MS127, San Francisco, CA 94121,United States
Abstract: Effective non-genetic disease modifying treatments for Huntington’s disease (HD) will necessarily target multiple diverse neurodegenerative processes triggered by mutant huntingtin. Neurotrophin receptors are well-positioned for this task as they regulate signaling pathways that largely overlap with signaling networks contributing to HD-related synaptic dysfunction, glial activation, excitotoxicity, and other degenerative processes. This review will discuss the contributions of disrupted neurotrophin receptor-related signaling to primary HD neuropathologies, and prospects for harnessing this signaling to develop therapeutics to counteract HD degenerative mechanisms. Application of the native protein ligands has been challenging pharmacologically, but progress has been made with the advent of small molecule compounds that can selectively bind to and activate specific Trk receptors or p75NTR to promote trophic and/or inhibit degenerative signaling in cell populations preferentially affected in HD.
Export Options
About this article
Cite this article as:
Simmons A. Danielle, Longo M. Frank and Massa M. Stephen*, Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease, CNS & Neurological Disorders - Drug Targets 2017; 16 (3) . https://dx.doi.org/10.2174/1871527315666161107093047
DOI https://dx.doi.org/10.2174/1871527315666161107093047 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prevalence of Anti-nuclear and Anti-phospholipid Antibodies in an Egyptian
Cohort with Schizophrenia: A Case-control Study
Current Rheumatology Reviews Lipophilicity and Other Parameters Affecting Brain Penetration
Current Medicinal Chemistry - Central Nervous System Agents Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury
Current Pharmaceutical Design Microglia and Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Metabolic Syndrome and Psychiatric Practice: Clinical and Management Issues
Current Psychiatry Reviews Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Recent Advances in Antiepileptic Herbal Medicine
Current Neuropharmacology Meet Our Editorial Board Member:
Current Neuropharmacology Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases
Current Drug Targets Synthesis, Anticonvulsant and Binding Interaction Study of Novel Piperamides with Bovine Serum Albumin by Fluorescence Spectroscopy
Central Nervous System Agents in Medicinal Chemistry BDZs, Designer BDZs and Z-drugs: Pharmacology and Misuse Insights
Current Pharmaceutical Design Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research High Temperature Unfolding Simulations of a Single-stranded DNA i-Motif
Current Physical Chemistry Nutritional and Pharmacological Management of Childhood Epilepsy: Ketogenic Diets and Common AEDs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Lamotrigine as an Effective Treatment for Behavioral Disorders
Letters in Drug Design & Discovery Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Subject Index To Volume 6
Current Topics in Medicinal Chemistry AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Spontaneous Recurrent Seizures Mediated Cardiac Dysfunction via mTOR Pathway Upregulation: A Putative Target for SUDEP Management
CNS & Neurological Disorders - Drug Targets Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry